Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Lung cancer symbols : AMGN save search
Non-small Cell Lung Cancer Drugs Market to Grow by USD 30.23 billion| Increasing Prevalence and Incidence of Non-small Cell Lung Cancer to Boost Market Growth | Technavio
Published: 2022-03-08 (Crawled : 08:00) - prnewswire.com
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -2.09%
H: 5.03%
C: 0.85%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.01%
H: 0.81%
C: -0.06%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
drug cel lung cancer cancer drug cancer growth
LUMAKRAS® (sotorasib) Receives Approval In Japan For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2022-01-20 (Crawled : 11:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.95%
H: 2.8%
C: 1.37%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.07%
lumakras approval cel lung cancer cancer
LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
ema lung cancer positive cancer chmp
Labcorp Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy
Published: 2021-07-01 (Crawled : 00:00) - biospace.com/
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: 0.36%
H: 0.61%
C: 0.42%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.0%
H: 1.38%
C: 1.3%
lung cancer therapy cancer approval diagnostic
New Drug Effective Against Lung Cancers Caused by Common Genetic Error
Published: 2021-06-04 (Crawled : 19:00) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
new drug genetic lung cancer cancer drug
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
Published: 2021-05-28 (Crawled : 21:00) - biospace.com/
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.59%
H: 0.91%
C: -0.14%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.59%
H: 0.91%
C: -0.14%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.73%
fda lung cancer cancer fda approval diagnostic
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy
Published: 2021-05-28 (Crawled : 17:00) - prnewswire.com
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: 0.82%
H: 2.28%
C: -0.95%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.73%
fda lung cancer therapy cancer drug fda approval approval
FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Published: 2021-05-28 (Crawled : 17:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.41%
H: 2.09%
C: 1.72%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.73%
treatment fda lung cancer cancer fda approval
Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
Published: 2021-04-19 (Crawled : 13:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.02%
H: 1.91%
C: -0.69%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -1.12%
H: 1.29%
C: 1.23%
lung cancer test cancer biomarkers
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
Published: 2021-04-12 (Crawled : 20:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: -4.44%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.17%
H: 0.6%
C: 0.17%
lung cancer results cancer trial
FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Published: 2021-02-16 (Crawled : 00:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.51%
H: 0.71%
C: -1.34%
treatment fda lung cancer cancer designation
Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Published: 2021-01-28 (Crawled : 20:08) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -1.14%
H: 0.63%
C: -1.43%
cancer ev lung cancer
Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer
Published: 2021-01-26 (Crawled : 23:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.2%
H: 0.97%
C: 0.78%
cancer lung cancer
Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020
Published: 2021-01-12 (Crawled : 19:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.19%
H: 0.7%
C: -0.22%
cancer lung cancer therapy
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
Published: 2020-12-16 (Crawled : 21:11) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.3%
H: 0.99%
C: 0.93%
fda cancer drug lung cancer new drug application
Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation
Published: 2020-12-08 (Crawled : 16:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.13%
H: 0.04%
C: -0.03%
cancer therapy lung cancer breakthrough therapy grant designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.